Indications for Keppra
Keppra is approved as adjunctive therapy to treat partial-onset seizures in patients aged 4 years or older with epilepsy, as adjunctive therapy in treating myoclonic seizures in patients aged 12 years or older with juvenile myoclonic epilepsy, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
For recent update, please go to http://www.epilepsy.com/newsfeed/pr_1174483801.html
